Search results
Structure Therapeutics Stock Soars on Obesity Pill Data
The Wall Street Journal· 2 days agoShares of Structure Therapeutics jumped more than 45% Monday after a new clinical study boosted...
Why docs should ditch 'just lose weight' advice
Futurity· 19 hours agoNutrition is a key determinant of health, but American physicians aren’t receiving effective training to counsel patients on the topic, according to a...
Type of weight loss surgery women undergo before pregnancy may influence children's weight gain
Medical Xpress· 2 days agoThe type of weight loss surgery women undergo before becoming pregnant may affect how much weight...
The best foods to eat for gut health
The Telegraph via Yahoo News· 3 hours agoNot so long ago, the five-a-day rule was the only dietary advice we seemed to need. According to the World Health Organisation, eating five daily...
Structure Therapeutics’ stock jumps on weight-loss-pill trial results
Market Watch· 2 days agogained more than 6% premarket on Monday after the company said its experimental weight-loss pill...
Eli Lilly's Wegovy rival Zepbound will help make weight-loss drug market worth $130 billion by 2030,...
Business Insider· 3 days agoThe anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs analysts said in a...
Study finds semaglutide associated with reduction in incidence and recurrence of alcohol-use...
Medical Xpress· 2 days agoThe team's findings, recently published in the journal Nature Communications, may suggest a possible...
The best foods to eat for gut health
Daily Telegraph· 3 hours ago“Other good gut health foods, particularly when it comes to promoting a healthy gut lining, include pumpkin, sweet potatoes, squash, nuts and also...
The 3 Most Undervalued Biotech Stocks to Buy in June 2024
InvestorPlace· 1 day agoUndervalued biotech stocks can offer some of the most explosive opportunities. Many times, biotech...
Goldman Sachs raises Eli Lilly 2030 GLP-1 medications forecast to $130bn By Investing.com
Investing.com· 6 days agoGoldman Sachs raises Eli Lilly 2030 GLP-1 medications forecast to $130bn
